Calidi Biotherapeutics Raises $4.6 Million Through Warrant Exercise

Calidi Biotherapeutics, Inc. has entered a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 6,595,000 shares of the Company’s common stock at a reduced price of $0.70, expected to raise approximately $4.6 million. The offering is expected to close on or about July 10, 2025, and the net proceeds will be used to advance clinical programs and operating expenses. The new warrants issued are part of a private placement and have not been registered under the Securities Act of 1933. The Company plans to file a registration statement for the resale of the shares issuable upon exercise of the new warrants.

Calidi Biotherapeutics is a clinical-stage biotechnology company developing targeted therapies for genetic medicines to treat diseases. The company’s Redtail platform allows for systemic delivery of viral vectors to reach tumor sites and deliver gene therapies effectively. The lead candidate from the Redtail platform targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Calidi is also developing protected virotherapies for injectable cancer indications. Forward-looking statements in this press release contain risks and uncertainties related to clinical trials and FDA approval. For more information, visit www.calidibio.com.

Read more at GlobeNewswire: Calidi Biotherapeutics Announces Exercise of Warrants for